Midatech Pharma Plc Kapitalrendite
Was ist das Kapitalrendite von Midatech Pharma Plc?
Kapitalrendite von Midatech Pharma Plc ist -192.91%
Was ist die Definition von Kapitalrendite?
Die Eigenkapitalrendite ist ein Maß für die Rentabilität eines Unternehmens im Verhältnis zum Buchwert des Eigenkapitals. Sie wird berechnet, indem das Nettoergebnis des Geschäftsjahres durch das gesamte Eigenkapital geteilt wird.
The return on equity (ROE) ROE is a measure of how well a company uses investments to generate earnings growth. ROE is used for comparing the performance of companies in the same industry. It indicated the management's ability to generate income from the equity available to it. ROEs of 15-20% are generally considered good. ROEs are also a factor in stock valuation, in association with other financial ratios. In general, stock prices are influenced by earnings per share (EPS), so that stock of a company with a 20% ROE will generally cost twice as much as one with a 10% ROE.
Kapitalrendite von Unternehmen in Health Care Sektor auf LSE im Vergleich zu Midatech Pharma Plc
Was macht Midatech Pharma Plc?
Midatech Pharma plc focuses on the research and development of oncology and rare disease products in the United Kingdom, rest of Europe, and internationally. The company is developing MTX110, a direct delivery treatment for diffuse intrinsic pontine glioma, medulloblastomas, and glioblastoma multiforme; MTX114, an immuno-suppressant for topical application in psoriasis; and MTD211 and MTD219 for central nervous system and transplant anti-rejection indications. It also offers drug delivery platforms, such as Q-Sphera, a polymer microsphere microtechnology used for sustained release drug delivery; MidaSolve, an oligosaccharide nanotechnology used to solubilize drugs so that they can be administered in liquid form directly and locally into tumors; and MidaCore, a gold nanoparticle used for targeting sites of disease by using chemotherapeutic agents or immunotherapeutic agents. The company was founded in 2000 and is headquartered in Cardiff, the United Kingdom.
Unternehmen mit kapitalrendite ähnlich Midatech Pharma Plc
- General Moly hat Kapitalrendite von -193.78%
- General Moly hat Kapitalrendite von -193.78%
- General Moly hat Kapitalrendite von -193.78%
- Totally Hip Technologies hat Kapitalrendite von -193.63%
- Sarytogan Graphite hat Kapitalrendite von -193.61%
- Jack Nathan Medical Corp hat Kapitalrendite von -193.17%
- Midatech Pharma Plc hat Kapitalrendite von -192.91%
- Applied Genetic Technologies Corp hat Kapitalrendite von -192.90%
- Krakatoa Resources hat Kapitalrendite von -192.87%
- Canopy Growth hat Kapitalrendite von -192.43%
- Hycroft Mining hat Kapitalrendite von -192.29%
- Revolve Renewable Power Corp hat Kapitalrendite von -192.27%
- GeNeuro SA hat Kapitalrendite von -192.10%